R
Robert L. Burton
Researcher at University of Alabama at Birmingham
Publications - 35
Citations - 1463
Robert L. Burton is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Pneumococcal conjugate vaccine & Heptavalent Pneumococcal Conjugate Vaccine. The author has an hindex of 21, co-authored 34 publications receiving 1353 citations.
Papers
More filters
Journal ArticleDOI
Semiquantitative Epstein-Barr Virus (EBV) Polymerase Chain Reaction for the Determination of Patients at Risk for EBV-Induced Lymphoproliferative Disease After Stem Cell Transplantation
Kenneth G. Lucas,Robert L. Burton,Sarah E. Zimmerman,Jinghong Wang,Kenneth Cornetta,Kent A. Robertson,Chao H. Lee,David J. Emanuel +7 more
TL;DR: The measurement of EBV viral load with semiquantitative PCR is useful in detecting EBV-LPD in high-risk patients before the onset of clinical symptoms, and results cannot substitute for clinical, radiographic, and pathological confirmation of this diagnosis.
Journal ArticleDOI
Pneumococcal vaccine and opsonic pneumococcal antibody.
TL;DR: A bioassay measuring the capacity of antibodies to opsonize pneumococci has been developed that replicates the in vivo mechanism of antibody protection and should therefore better reflect protection by vaccine-induced antibodies.
Journal ArticleDOI
Low-cost, high-throughput, automated counting of bacterial colonies†‡
Matthew L. Clarke,Robert L. Burton,A. Nayo Hill,Maritoni Litorja,Moon H. Nahm,Jeeseong Hwang +5 more
TL;DR: A low‐cost, high-throughput colony counting system consisting of colony counting software and a consumer‐grade digital camera or document scanner that can count bacterial colonies as part of a high‐throughput multiplexed opsonophagocytic killing assay used to characterize pneumococcal vaccine efficacy is presented.
Journal ArticleDOI
Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65.
Qi Sun,Karen E. Pollok,Robert L. Burton,Li Jun Dai,William J. Britt,David Emanuel,Kenneth G. Lucas +6 more
TL;DR: The results demonstrate that BLCL can be used as APC to stimulate expansion of EBV- and CMV-specific CTL simultaneously, and have potential implications for posttransplant CMV and EBV immunotherapy in recipients of allogeneic stem cell transplants.
Journal ArticleDOI
Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
TL;DR: In conclusion, adoptive immunotherapy with allogeneic EBV‐specific CTL is safe and may have efficacy in patients with high‐risk or refractoryEBV‐related tumours.